New combo therapy takes on advanced cancers

NCT ID NCT07639450

Recruiting now Disease control Sponsor: Hefei Xinzhu Biological Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 adults aged 18-75 with good performance status may join.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colorectal cancer cutaneous melanoma head and neck squamous cell carcinoma metastatic melanoma non-small cell lung carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID TUMORS

Contacts and locations

Locations

Corner Edith & Platt Streets, , NSW 2298 Australia
NOT_YET_RECRUITING

Waratah, New South Wales, 2298, Australia
GenesisCare Research
NOT_YET_RECRUITING

Saint Leonards, New South Wales, 2065, Australia
Henan Cancer Hospital
NOT_YET_RECRUITING

Zhengzhou, Zhengzhou, 450000, China
Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, Hunan, 410013, China
San Clinical Trials Unit
NOT_YET_RECRUITING

Wahroonga, New South Wales, 2076, Australia
Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.